Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Short Interest Update

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) saw a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 173,306 shares, a decrease of 34.0% from the July 30th total of 262,477 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily volume of 271,752 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TVRD shares. HC Wainwright began coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 8th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. BTIG Research lowered their price objective on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds have recently made changes to their positions in TVRD. American Financial Group Inc. purchased a new position in Tvardi Therapeutics during the 4th quarter valued at approximately $962,000. Vestal Point Capital LP purchased a new stake in shares of Tvardi Therapeutics during the 3rd quarter worth approximately $6,508,000. Geode Capital Management LLC bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $2,617,000. BlackRock Inc. bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $181,000. Finally, Invesco Ltd. purchased a new position in shares of Tvardi Therapeutics in the third quarter valued at $3,219,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $1.75 on Wednesday. The firm has a fifty day moving average price of $2.29 and a 200 day moving average price of $3.00. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The firm has a market cap of $23.28 million, a price-to-earnings ratio of -0.63 and a beta of 0.32.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.